摘要
目的:探讨联合检测血清糖类抗原标志物在女性绝经前后卵巢浆液性癌诊断中的价值。方法:采用回顾性研究方法,选择2016年8月到至2018年2月在我院肿瘤科进行检测的绝经前后卵巢浆液性癌患者60例(癌变组)与绝经前后健康体检者60例(健康对照组),检测其血清癌胚抗原(carcino-embryonic antigen,CEA)、人附睾蛋白4(human epididymis protein 4,HE4)和糖链抗原125(carbohydrate antigen 125,CA125)的水平,并分析其与患者的临床病理特征与随访预后的相关性。结果:癌变组血清CEA、HE4、CA125水平及阳性表达率都均显著高于健康对照组(P<0.05)。在癌变组60例患者中,随着病理分期增加、分化程度的减少、淋巴结转移与死亡情况的发生,血清CEA、HE4、CA125的阳性表达率显著升高,对比差异有统计学意义(P<0.05)。同时在120例人群中,联合诊断为卵巢浆液性癌者54例,联合诊断的敏感性与特异性分别为90.0%和100.0%。结论:绝经前后女性卵巢浆液性癌患者血清糖类抗原标志物-CEA、HE4、CA12水平均呈现高表达,可能作为绝经前后女性卵巢浆液性癌诊断与预后预测的参考指标。
Objective: To investigate the values of combined detection of serum carbohydrate antigen markers in the diagnosis of ovarian serous carcinoma in women before and after menopause. Methods: Used a retrospective study, from August 2016 to February2018 60 patients with ovarian serous carcinoma before and after menopause(canceration group) and 60 healthy subjects before and after menopause(health control group) were selected, the serum levels of CEA, HE4 and CA125 were detected, and their correlation with clinicopathological features and follow-up prognosis was analyzed. Results: The levels of serum CEA, HE4, CA125 and positive expression rate in the canceration group were significantly higher than those in the healthy control group(P<0.05). Among the 60 patients in the carcinogenesis group, with the increase of pathological stage, reduction of differentiation, lymph node metastasis and mortality, the positive expression rate of serum CEA, HE4 and CA125 increased significantly, the difference was statistically significant(P<0.05). In the 120 cases, there were 54 cases of ovarian serous carcinoma were combined, the sensitivity and specificity of combined diagnosis were 90.0%and 100.0%, respectively. Conclusion: The levels of serum carbohydrate antigen markers CEA, HE4 and CA12 in premenopausal and postmenopausal women with ovarian serous carcinoma were all increased, which may serve as a reference index for the diagnosis and prognosis prediction of ovarian serous carcinoma in premenopausal and postmenopausal women.
作者
赵珊
路红
刘军辉
张楠
刘懿
ZHAO Shan;LU Hong;LIU Jun-hui;ZHANG Nan;LIU Yi(Laboratory Department,The First Affiliated Hospital of Xi'an Jiao Tong University,Xi'an,Shaanxi,710061,China;Laboratory Department,Chengcheng County Hospital,Weinan,Shaanxi,715200,China)
出处
《现代生物医学进展》
CAS
2019年第11期2108-2111,2166,共5页
Progress in Modern Biomedicine
基金
陕西省社会发展科技攻关项目(2016SF-217)
关键词
癌胚抗原
人附睾蛋白4
糖链抗原125
绝经
卵巢浆液性癌
Carcino-embryonic antigen
Human epididymis protein 4
Sugar chain antigen 125
Menopause
Ovarian serous carcinoma
